Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 110

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 110
---
RO will expire) based on information as prepared by Aadi management in connection with Aadi’s evaluation of the Divestiture. The non risk-adjusted FYARRO projections were not probability-adjusted and included, among other things, the following key assumptions regarding the FYARRO business and 2025-2039 costs of goods sold (“COGS”), 2025-2039 research and development (“R&D”) expense, and 2025-2039 selling, general and administrative (“SG&A”) expense, in each case as to which there can be no assurance:

| • |     | revenue projections for the FYARRO business in the United States for 2025 and 2026 based on bottom-up demand analysis, with an assumed 3% annual growth rate thereafter from 2027-2039; |

| • |     | no additional indications beyond PEComa or associated development spend; |

| • |     | FYARRO is commercialized by a partner in the European Union in 2027 and a 20% royalty is paid on net sales in the 
 territory;                                                                                                        |

| • |     | $3.0 million and $4.0 million of COGS in 2025 and 2026, respectively; |

| • |     | COGS equal to 11.5% of U.S. revenue from 2026-2039, incorporating a 7.5% royalty payable to BMS under the 
 existing license agreement with BMS;                                                                      |

| • |     | for R&D expense, an aggregate of $166.0 million in unadjusted CMC and quality assurance expenses for 
 2025-2039;                                                                                           |

| • |     | for R&D expense, $11.0 million and $10.0 million in unadjusted CMC and quality assurance expenses for 2025 
 and 2026, respectively;                                                                                    |

- 69 -

| • |     | for SG&A expense, an aggregate of $116.0 million in unadjusted commercial and general and administrative 
 expenses, and no public company operating expenses;                                                      |

| • |     | $6.0 million of SG&A expense in each of 2025 and 2026; |

| • |     | a 25% tax rate and no utilization of net operating losses; and |

| • |     | patent protection for FYARRO expiring in 2039. |

The non-adjustedFYARRO projections for the applicable periods